Analytical Data
-
Gene name
CRTAM
- Application
-
Alternative Names
CRTAM;Cytotoxic and regulatory T-cell molecule
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O95727
-
Expression Region
18-286aa
-
AA Sequence
SLTNHTETIT VEEGQTLTLK CVTSLRKNSS LQWLTPSGFT IFLNEYPALK NSKYQLLHHS ANQLSITVPN VTLQDEGVYK CLHYSDSVST KEVKVIVLAT PFKPILEASV IRKQNGEEHV VLMCSTMRSK PPPQITWLLG NSMEVSGGTL HEFETDGKKC NTTSTLIIHT YGKNSTVDCI IRHRGLQGRK LVAPFRFEDL VTDEETASDA LERNSLSSQD PQQPTSTVSV TEDSSTSEID KEEKEQTTQD PDLTTEANPQ YLGLARKKS
-
Molecular Weight
59 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CRTAM (Cytotoxicity-Related Adhesion Molecule) is a cell surface protein that plays a crucial role in the immune response, particularly in the interaction between T cells and target cells. It belongs to the immunoglobulin superfamily and is predominantly expressed on cytotoxic T lymphocytes and natural killer cells. The study of CRTAM and its recombinant proteins has gained importance due to its potential implications in enhancing anti-tumor immunity and improving immunotherapeutic strategies. Research has shown that CRTAM can facilitate the adhesion of T cells to target cells, promoting the cytotoxic activity necessary for an effective immune response against cancer cells. Understanding the structural and functional properties of CRTAM, along with the development of recombinant forms of the protein, may lead to the design of novel therapeutic approaches for cancer treatment and other diseases where immune modulation is beneficial. Moreover, the ability to produce CRTAM as a recombinant protein allows scientists to investigate its biological functions and interactions in greater detail, paving the way for new strategies to harness the immune system in combating tumors and infectious diseases. This research is particularly relevant in the context of developing personalized medicine and targeted therapies that could improve patient outcomes in a range of malignancies. Overall, the exploration of CRTAM as a recombinant protein offers valuable insights into its role in immune regulation and holds promise for advancing immunotherapy.
